AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure

AnaptysBio (ANAB -35.3%) has lost more than a third today following its pre-market announcement of the failure of imsidolimab to meet the primary endpoint in a mid-stage study for moderate-to-severe palmoplantar pustulosis.